EMA's access to documents policy would have failed to prevent cases of withheld information
This article was originally published in SRA
As part of its attempts to improve transparency, the European Medicines Agency has adopted a new policy on increasing public access to documents1. However, delegates at the recent EMA/TOPRA meeting in London2 said that it would not have prevented certain instances where information had been withheld from the public.
You may also be interested in...
Draft guidelines due out for consultation this week in Italy are expected to shed more light on what companies will have to reveal during pricing and reimbursement negotiations.
Germany is for the first time to adopt national guidelines on prescribing biologics and biosimilars in a move towards increasing biosimilar uptake.
EFPIA, the European Federation of Pharmaceutical Industries and Associations, has put forward what it thinks the European regulatory network strategy to 2025 should prioritize.